Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deoxyamidinoproclavaminic acid is a small molecule organic compound classified as a monobactam, featuring a beta-lactam ring structure. It is also considered a guanidine, monocarboxylic acid, and an L‑arginine derivative. Functionally, it is related to proclavaminic acid and represents an intermediate in the biosynthetic pathway of clavulanic acid—a well-known beta-lactamase inhibitor used in combination with antibiotics. Deoxyamidinoproclavaminic acid itself has not been approved for clinical use and remains an experimental compound with no current indications or clinical trials[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deoxyamidinoproclavaminic acid.